State Street’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

State Street’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-202,247	Closed	-$44.5K	–	4710
2023 Q2	$44.5K	Buy	202,247 +159,000	+368%	+$36.6K	﹤0.01%	4448
2023 Q1	$13.6K	Hold	43,247	–	–	﹤0.01%	4724
2022 Q4	$51K	Hold	43,247	–	–	﹤0.01%	4554
2022 Q3	$40K	Buy	43,247 +15,200	+54%	+$23.6K	﹤0.01%	4706
2022 Q2	$31K	Buy	28,047 +1,600	+6%	+$1.99K	﹤0.01%	4816
2022 Q1	$47K	Hold	26,447	–	–	﹤0.01%	4805
2021 Q4	$62K	Hold	26,447	–	–	﹤0.01%	4667
2021 Q3	$97K	Buy	+26,447	New	+$122K	﹤0.01%	4555

Other funds holding ARDS

Wealth Architects Mountain View, California $1.27B AUM 36.93% 1-Year Est. Return

State Street's ARDS Position: Q3 2023 in Review

State Street sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 202,247 shares — an estimated $44.5K sold.

State Street first reported a position in ARDS in Q3 2021 and held it in 8 quarters. The position peaked at $97K in Q3 2021. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.

State Street reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
State Street sold 202,247 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $44.5K.
State Street first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 8 quarters.
State Street's Aridis Pharmaceuticals Inc. Common Stock position peaked at $97K in Q3 2021.
1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.